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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: To investigate the continuous therapeutic effects and urinary inconti-
nence severity after repeated detrusor injections of 200-U of onabotulinumtoxinA (BoNT-A)
in chronic spinal cord-injured (SCI) patients.
Methods: Between 2006 and 2010, patients with chronic SCI and refractory neurogenic de-
trusor overactivity (DO) were treated with repeated sets of 200-U BoNT-A injected into 20
sites every 6 months. All patients underwent urological examinations and video-
urodynamic studies at baseline and after each BoNT-A treatment. The outcomes were
measured using Urogenital Distress Inventory 6-item short form (UDI-6) for urinary inconti-
nence. The severity of urinary incontinence and urodynamic parameters were compared
after each BoNT-A injection.
Results: A total of 59 SCI patients with a mean age of 42.1  13.1 years were enrolled. The
UDI-6 incontinence scores persistently improved for up to three injections. The rate of dry-
ness and mild incontinence reported by patients persistently improved from 25.4% at base-
line to 74% at 3 months after the fourth injection, but decreased slightly after the fourth
injection. The overall satisfaction rate after single or repeated injections was 59.3% (35 pa-
tients), and the failure rate was 33.9% (20 patients), and discontinuation rate owing to
adverse events (2 recurrent UTI, 2 autonomic dysreflexia) was 6.8% (4 patients). Among
the 20 patients who reported failure to treatment, 10 patients (16.9%) reported no signifi-
cant improvement after one or repeated injections, eight converted to augmentation enter-
ocystoplasty.ave no conflicts of interest relevant to this article.
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584 S.-F. Chen, H.-C. KuoConclusion: Repeated 200-U BoNT-A injections every 6 months for neurogenic DO in chronic
SCI patients provided a satisfactory initial outcome. However, only 20% patients continued
the repeated treatment.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Spinal cord injury (SCI) is a significant cause of morbidity
and mortality in developing countries, with a global annual
incidence of 1:25,000.1 Neurogenic voiding dysfunction and
urinary symptoms in patients with SCI lead to several
complications. If not well managed, high intravesical
pressure will damage the upper urinary tract, causing renal
scarring and chronic renal insufficiency, which impair the
quality of life.2 The first-line treatment for SCI induced
neurogenic detrusor overactivity (DO) is antimuscarinic
agents with or without clean intermittent catheterization
(CIC).3,4 However, most of the patients have an incomplete
response to antimuscarinic agents, which can also cause
undesirable systemic side effects.5
OnabotulinumtoxinA (BoNT-A) detrusor injections were
introduced in 2000 as a minimally invasive treatment option
for neurogenic DO.6 In addition to the benefit of decreased
detrusor pressure to prevent renal damage, it significantly
improved quality of life.7 In 2011, a global Phase 3 clinical
trial concluded both 200-U and 300-U injections provided
the same therapeutic effect.8 However, most previously
published studies used 300-U BoNT-A detrusor injections;
only a few studies focused on 200-U BoNT-A injections for
the treatment of neurogenic DO. As most patients with
neurogenic DO require repeated treatments, the efficacy
and safety of multiple BoNT-A injections need to be
addressed. This study investigated the therapeutic effects
of repeated 200-U BoNT-A injections in the detrusor muscle
for the treatment of urinary incontinence and refractory
neurogenic DO among SCI patients. We also investigated the
adherence of SCI patients to repeated BoNT-A injections
throughout the study course.Methods
Patients with SCI and neurogenic DO, requiring CIC or not,
and who were refractory to antimuscarinic treatment were
consecutively enrolled in this prospective study. Video-
urodynamic studies (VUDS) were routinely performed prior
to enrollment to prove the presence of DO with or without
detrusor sphincter dyssynergia, and exclude the patients
with detrusor underactivity, anatomical obstruction, or
intrinsic sphincter deficiency. Patients were also excluded
if they had an active urinary tract infection at enrollment,
urinary tract cancer, history of lower urinary tract surgery,
or chronic systemic diseases such as congestive heart fail-
ure and chronic renal failure.
VUDS was performed according to the recommendations
of the International Continence Society.9 The urodynamic
parameters of cystometric bladder capacity (CBC),
maximum flow rate (Qmax), post-voiding residual (PVR)
volume, voided volume, involuntary detrusor contraction(IDC) and voiding detrusor pressure at Qmax (Pdet.Qmax)
were recorded in detail. In addition, the lower urinary tract
symptoms were evaluated using the Urogenital Distress In-
ventory short form (UDI-6) questionnaire.
The patients were designed to receive initial four
repeated injections each of 200-U of BoNT-A (Allergan,
Irvine, CA, USA) in the detrusor muscle at baseline and
every 6 months thereafter. The BoNT-A injections were
performed under light intravenous general anesthesia in
the operating room. The 200-U BoNT-A was diluted with
20 mL of normal saline and the diluted solution was injec-
ted into 20 sites in the bladder wall, excluding the bladder
trigone. The patients were evaluated every 3 months for
the therapeutic effects, quality of life in urinary inconti-
nence, and VUDS for evaluation of the bladder condition.
All patients were scheduled for four sets of BoNT-A in-
jections (Phase I). However, patients were also allowed to
withdraw from the trial if they were dissatisfied with the
treatment outcome, having intolerable adverse events, or
were effective to treatment but did not want to continue
the injection. After completion of four sets of BoNT-A in-
jection and follow-up, patients were allowed to receive
two additional BoNT-A injections every 6 months (Phase II)
if they wished to continue this mode of treatment for their
urinary incontinence. The causes of discontinuation of
BoNT-A injection were analyzed, and patients were
considered to have effective treatment based on their
subjective reports.
This study was approved by the Ethics Committee of Tzu
Chi General Hospital, Hualien, Taiwan (TCGH 098-53 and
098-088); written, informed consent to participate was
obtained at enrollment. All patients had been informed and
educated for CIC after treatment. Patients had to agree to
perform CIC prior to when they were enrolled in the study.
The primary efficacy parameter was the severity of
urinary incontinence (caused by all etiologies) as perceived
by the patient’s subjective scoring of urinary leakage at
each follow-up visit. The incontinence severity score was
adapted from three incontinence items from the UDI-6. The
severity of urinary incontinence was graded as dry if the
sum of UDI-6 incontinence items was 0, mild in the sum of
1e3, moderate in the sum of 4e6, and severe in the sum of
7e9. Secondary efficacy parameters were the changes in
VUDS parameters at 3 months and 6 months after each set
of BoNT-A injections. Any adverse events were also recor-
ded throughout the study. Urinary tract infection was
defined as a febrile episode with a white blood cell count of
more than 10 cells per high-power field on urinalysis.
Asymptomatic pyuria was not considered an adverse event.
Results
A total of 59 patients with SCI and neurogenic DO were
enrolled in this study, including 21 women and 38 men.
Repeated Botox injections for neurogenic bladder 585Their mean age was 42.1  13.1 years (range: 22e74 years)
and the mean injury duration was 8.7  8.1 years. Higher-
level SCI was the most common, including 26 patients with
cervical SCI, 28 with thoracic SCI, and five with lumbar SCI.
Among all patients, 39 were classified as ASIA-A, 9 ASIA-B, 5
ASIA-C, 5 ASIA-D, and 1 ASIA-E according to the American
Spinal Injury Association (ASIA) Classification.10 All patients
had urinary incontinence at enrollment.
After the first injection, 7 patients did not come back for
follow-up because of adverse events (in 4 patients) or failed
treatment (in 3 patients). Only 52 patients were available
for the second follow-up visit. However, not all patients
continued the subsequent BoNT-A injections because of
different causes. Among all patients, 43 received two sets
of BoNT-A injection and required follow-up visits, 31
received three sets, 27 received four sets, 15 received five
sets, and only 11 received six sets of injection. Fig. 1 shows
the flow diagram of patients. The overall satisfaction rate
after single or repeated injections was 59.3% (35 patients),
the failure rate was 33.9% (20 patients), and the discon-
tinuation rate due to adverse events (2 individuals had
recurrent UTI, 2 individuals had autonomic dysreflexia) was
6.8% (4 patients).
Fig. 2 shows the continuous change in incontinence
severity among patients who received repeated BoNT-A
injections and follow-up. The initial therapeutic effect of
the first 200-U BoNT-A injection was satisfactory. At 3
months after the first injection, 33 (63.5%) of 52 patients
reported completely dry (7 patients, 13.5%) or mild incon-
tinence (26 patients, 50%). The rates of dry (6 patients,
11.5%) and mild incontinence (22 patients, 42.3%) declined
slightly at 6 months after the first injection, but returned to
a higher level 3 months after the second injection (dry: 13Figure 1 The flow diagram of patients receiving repeated BoNT-
and failed the treatment. BoNT-A Z onabotulinumtoxinA.patients, 30.2%; mild incontinence: 15 patients, 34.9%).
The incontinence severity improved consistently up to the
time of 3 months after the fourth injection (dry: 8 patients,
29.6%; mild incontinence: 12 patients, 44.4%).
The subjective symptoms of incontinence as assessed by
the UDI-6 improved dramatically during the course of the
first three sets of injections at both 3 months and 6 months
after injection. Moderate and severe incontinence was
noted in 74.6% of patients at baseline, but in only 25.9% and
44.4% at 3 months and 6 months after the fourth injection,
respectively. The therapeutic effect decreased gradually
after the fourth injection. The percentage of moderate and
severe incontinence was 46.7% and 36.4% at 3 months after
the fifth and sixth injections, and 50% and 40% at 6 months
after the fifth and sixth injections, respectively.
The changes in urodynamic parameters after repeated
BoNT-A injections are given in Table 1. Significant increases
in CBC and PVR volumes, and a significant decrease in
Pdet.Qmax were noted 3 months and 6 months after each
set of BoNT-A injections. The CBC, bladder compliance, and
Pdet.Qmax were consistent throughout the treatment
course. CBC increased from 228 mL at baseline to more
than 400 mL, but slightly decreased after the fourth set of
injections. The Pdet.Qmax decreased to less than
25 cmH2O, which is considered a level safe enough to pre-
vent upper urinary tract damage. Furthermore, the PVR
volume also increased along with the incremental CBC
increase.
Of the 52 study patients with available follow-up after
the first injection, adverse events occurred in 13 patients
(25%) who developed urinary tract infection and in four
patients (7.7%) who had post-operative gross hematuria. By
contrast, the occurrence of IDC in urodynamic studies wasA injections, and the number of patients with effective results
Figure 2 Urinary incontinence severity at 3-month and 6-month follow-ups after each set of 200-U BoNT-A detrusor injections.
Parentheses indicate available follow-up patient numbers. BoNT-A Z onabotulinumtoxinA.
586 S.-F. Chen, H.-C. Kuonoted in 93.2% (53/59 patients) of patients at baseline.
After BoNT-A injection, the incidence of IDC decreased at 3
months, and increased slightly at 6 months after each in-
jection (Fig. 3). Nonetheless, we still observed that IDC was
consistently higher at 6 months than at 3 months after each
injection, which indicated that the therapeutic effect was
greater at 3 months, but decreased at 6 months after each
BoNT-A injection.
After the first BoNT-A injection 17 of the 52 patients did
not continued treatment because they were satisfied to the
first treatment (n Z 5) or second treatment (n Z 12).
Overall, 20 individuals reported failure to one or repeated
BoNT-A injections, 10 (16.9%) individuals had improvement
fluctuated after repeated injections, and 10 (16.9%) in-
dividuals reported no significant improvement after one or
repeated injections. Eight patients with ineffective BoNT-A
treatment outcome converted to augmentation enter-
ocystoplasty for permanent correction and a better treat-
ment outcome.Discussion
Minimally invasive BoNT-A injections into the detrusor
muscle improved clinical and urodynamic parameters and
quality of life in patients with refractory neurogenic DO in
several open-label studies.1113 In our previous study, the
success rate was 73.3% in SCI patients with neurogenic DO
who received a single set of detrusor injections of 200-U
BoNT-A, and the therapeutic effects lasted for 3e9
months (mean: 5.3 months).14 Based on this preliminary
result, the injection protocol was designed as repeated
injections every 6 months in order to observe the consis-
tency of therapeutic effects of the repeated sets of BoNT-A
injections.
The dose of BoNT-A for neurogenic DO treatment was
controversial until the recent global Phase 3, multicenter
trials, in which both 200-U and 300-U of BoNT-A significantly
reduced urinary incontinence and improved urodynamic
parameters and quality of life in patients with neurogenic
DO. No clinically relevant difference in efficacy or durationof effect was observed between the two doses, and the
200-U dosage had fewer adverse effects.8,15 After BoNT-A
treatment, 62.9% of patients in the 200-U group and
61.6% in the 300-U group achieved the subjective primary
treatment goal of dryness.16 This evidence indicates that
200-U BoNT-A injections provide a satisfactory initial
outcome. The US Food and Drug Administration approved
the 200-U BoNT-A dosage for the treatment of neurogenic
DO associated with conditions such as SCI and multiple
sclerosis in 2011.
Bladder management for neurogenic DO should meet
three main objectives: low-pressure urine storage, low-
pressure voiding, and adequate urine drainage.12 However,
from the patient’s point of view, the most important goals
of treatment are continence and good tolerability of ther-
apy. Kalsi et al7 measured the changes in the quality of life
at 4 weeks and 16 weeks after treatment with BoNT-A
detrusor injections using the short form of the UDI-6 and
Incontinence Impact Questionnaire. The results showed
significant improvement after treatment, which is
compatible with our previous study.17 In another study, the
proportion of patients without IDC 6 weeks after treatment
with 200-U of BoNT-A was 64% (81/127).15 In this study, we
found no urodynamic IDC in 42.6% (23/54) of patients 3
months after the first 200-U BoNT-A injection, whereas the
proportion was 52.4% (22/42) at 3 months after the second
200-U injection. Nonetheless, the occurrence of IDC fluc-
tuated after each injection. It is possible that 200-U of
BoNT-A might not be adequate in abolishing all IDC, espe-
cially at 6 months after injection when the BoNT-A effect
has waned.
Haferkamp et al18 reported resprouting of the nerve
endings after an interval of about 9 months after BoNT-A
detrusor injection, with no significant ultrastructural
detrusor changes found in the biopsy tissue. Owing to the
reversible pharmacological effect of BoNT-A, repeated
BoNT-A injections are necessary to maintain a satisfactory
outcome. Grosse et al19 found that repeated 300-U BoNT-A
detrusor injections on demand slightly reduced the average
interval between the third and fourth treatments compared
to the interval between the first and second, and the
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Repeated Botox injections for neurogenic bladder 587second and third treatments. However, this difference was
not statistically significant. According to the results of the
extended Phase 3 clinical trial, the median time to patient
retreatment request was greater for 200-U and 300-U BoNT-
A than for placebo (256 days and 254 days, respectively, vs.
92 days).15 When the patients develop botulinum resis-
tance, subsequent injections might be less effective. When
the therapeutic results of these studies and our results are
compared, too frequent injections for neurogenic DO might
not have advantage in the long-term success.
Incontinence is the most bothersome factor that affects
the quality of life in SCI patients. We found that after the
fourth 200-U BoNT-A injection, although CBC and Pdet.Q-
max were still in the acceptable range, the percentage of
patients with moderate or severe urinary incontinence
increased, which caused a high withdrawal rate during the
study period and a decrease in the satisfaction rating. In
this study, 10 patients discontinued BoNT-A treatment
because of the perception of no significant improvement
and 10 other patients discontinued the treatment because
of the fluctuated therapeutic outcome not meeting their
expectations. This result is also compatible with a previous
study showing that post-treatment changes in CBC and
Pdet.Qmax did not correlate with the changes in the quality
of life scores or those of the symptom severity recorded in
bladder diaries.7
In a recent report of patients receiving intravesical
BoNT-A for overactive bladder over a period of 7 years,
61.3% (84/137) of patients had discontinued intravesical
BoNT-A therapy at 36 months, with a 63.8% (51/80)
discontinuation rate at 60 months.20 The main reasons for
discontinuation were tolerability issues, mainly urinary
tract infections and the need for CIC. Primary and sec-
ondary losses of efficacy were of secondary importance.
Therefore, patients with neurogenic DO may also discon-
tinue repeated BoNT-A injections for the same reasons.
Urinary retention was not defined as an adverse event
because the therapeutic effect was defined as complete
dryness so that urinary retention was a necessary effect.
Nonetheless, study has shown that about 70% of patients
require periodic CIC.12 SCI patients might have unrealistic
expectations regarding the BoNT-A treatment; however,
the improvement of urinary incontinence severity after
repeated BoNT-A injections could not meet the patients’
expectations.
Although the effects of BoNT-A were promising, the
maintenance rate is very low in this study. We assumed that
this was mainly because the therapeutic effect did not
meet their initial expectations. Although CBC and Pdet.Q-
max were still in the acceptable range after repeated
BoNT-A injections, the percentage of improvement in uri-
nary incontinence was not so significant. By contrast, most
patients were inconvenient to take medical treatment
because of restrictive activity. The last problem was the
adverse effect of UTI. Around one-third of patients got UTI
after BoNT-A injection. The high percentage of UTI may be
because of urinary retention and failure to perform CIC
regularly.
One of the limitations of this study is the small number
of patients and lack of a control arm. The second limitation
is that some of the patients dropped out of the study
because of lack of satisfaction with the treatment or
Figure 3 Percentage change in patients without involuntary detrusor contraction (non-IDC) at 3-month and 6-month follow-ups
after each set of 200-U BoNT-A detrusor injections. Parentheses indicate the number of patients at each time point.
BoNT-A Z onabotulinumtoxinA; IDC Z involuntary detrusor contraction.
588 S.-F. Chen, H.-C. Kuopreference for a permanent correction such as enter-
ocystoplasty. However, the overall study results can reflect
the real life practice of patients’ acceptance of this novel
treatment modality for neurogenic DO and urinary
incontinence.
In conclusion, repeated 200-U BoNT-A detrusor in-
jections every 6 months provide a satisfactory initial
outcome for treatment of patients with neurogenic DO and
urinary incontinence due to chronic SCI. However, the
improvement in incontinence severity was not consistent
after each injection, and the patients’ adherence rate to
repeated BoNT-A injections was not high as we expected.References
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